Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina
Key result
Abciximab did not improve 1-year mortality compared with placebo in patients with non-ST-elevation acute coronary syndrome (8.2% vs 7.8%; HR 1.1, 95% CI 0.86-1.29 for 24-hour infusion).
Why the study?
Does abciximab reduce 1-year mortality in patients with NSTE-ACS who are not scheduled for early coronary intervention?
Population
7,800 patients with acute coronary syndrome without ST elevation documented by either elevated cardiac…
Comparison
Abciximab bolus followed by either a 24-hour… vs Matching placebo.
Design
RCT, Randomized to abciximab bolus and 24-hour infusion, abciximab bolus and…
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Abciximab confers no benefit in medically managed NSTE-ACS; leaves open optimal GP IIb/IIIa use in this population.
Study Design
Type
RCT (n=7,800)
Blinding
Placebo-controlled
Randomization
Randomized
Structured PICO
Does abciximab reduce 1-year mortality in patients with NSTE-ACS who are not scheduled for early coronary intervention?
P
Population
7,800 patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention, followed for 1 year.
I
Intervention
Abciximab bolus followed by either a 24-hour infusion or a 48-hour infusion.
C
Comparator
Matching placebo.
O
Outcome
1-year mortality.hard clinical
Main Result
Hazard Ratio: 1.1 (95% CI 0.86–1.29)
Absolute Event Rate: 8.2% vs 7.8%
In patients with NSTE-ACS managed medically without early revascularization, abciximab does not improve 1-year survival and is associated with excess mortality in subgroups with negative troponin or elevated CRP.
Cite This Study
Ottervanger et al. (2003) conducted an RCT in Acute coronary syndrome without ST elevation (n=7,800). Abciximab vs. Matching placebo was evaluated on 1-year mortality (HR 1.1, 95% CI 0.86-1.29). Abciximab did not improve 1-year mortality compared with placebo in patients with non-ST-elevation acute coronary syndrome (8.2% vs 7.8%; HR 1.1, 95% CI 0.86-1.29 for 24-hour infusion).